A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer | Zendy

Soonmyung Paik | Zendy; Steven Shak | Zendy; Gong Tang | Zendy; Chungyeul Kim | Zendy; Joffre Baker | Zendy; Maureen Cronin | Zendy; Frederick L. Baehner | Zendy; Michael G. Walker | Zendy; Drew Watson | Zendy; Taesung Park | Zendy; W. Douglas B. Hiller | Zendy; Edwin R. Fisher | Zendy; D. Lawrence Wickerham | Zendy; John Bryant | Zendy; Norman Wolmark | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

Author(s) -

Soonmyung Paik,

Steven Shak,

Gong Tang,

Chungyeul Kim,

Joffre Baker,

Maureen Cronin,

Frederick L. Baehner,

Michael G. Walker,

Drew Watson,

Taesung Park,

W. Douglas B. Hiller,

Edwin R. Fisher,

D. Lawrence Wickerham,

John Bryant,

Norman Wolmark

Publication year - 2004

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa041588

Subject(s) - medicine , confidence interval , breast cancer , oncology , tamoxifen , proportional hazards model , relative risk , cancer , estrogen receptor , prospective cohort study , lymph node , gynecology , gastroenterology

The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research